CTOs on the Move

PDi-Pharmaceuticals

www.pdi.ca

 
PDi-Pharmaceuticals is a Aurora, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.pdi.ca
  • 242 Earl Stewart DR PO Box 10 Stn Main
    Aurora, ON CAN L4G 3H1
  • Phone: 905.886.7886

Executives

Name Title Contact Details

Similar Companies

FloraWorks

FloraWorks is a biotech enterprise that specializes in discovering rare and novel cannabinoids for commercial and therapeutic applications. They develop and patent scaled manufacturing pathways for cannabinoids with a high potential for therapeutic use...

Anchen Pharmaceuticals Inc

Anchen Pharmaceuticals Inc is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nestle Health Science

At Nestlé Health Science, we’re advancing nutritional therapy to change the approach of managing your health. Behind our pioneering company are people who are driving breakthroughs and innovating for impact. Here, you have the chance to change the course of health and your career. Our people are exploring new territory and breaking new ground in areas such as GI, critical care, surgery, oncology, healthy ageing, food allergy, obesity, brain health and pediatrics. They are changing the way doctors think about meeting the nutritional needs of patients, and the way patients and consumers manage their own health. They know the faces, hear the stories and celebrate the successes of people who had their lives transformed thanks to Nestlé Health Science solutions. Be part of a journey that changes the course of health.

B F Ascher and Company Inc

B.F. Ascher is a privately held over-the-counter healthcare company

Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy.